• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 19, 2014

View Archived Issues

Avonex(t): FDA gives nod to Plegridy for MS, oral Tecfidera still Biogen mouth that roared

Biogen Idec Inc. is keeping its injectable bases covered in relapsing multiple sclerosis (RMS) with the approval Friday of Plegridy (peginterferon beta-1a), given by an auto-injector pen or prefilled syringe every two weeks, a significant half-life advantage over the firm's Avonex (interferon beta-1a) for RMS, given weekly. Read More

BIA, ABPI launch campaign seeking biosimilars guidelines

LONDON – With the number of biosimilars approved in Europe on the rise, the UK Bioindustry Association (BIA) and the Association of the British Pharmaceutical Industry (ABPI) have joined forces in a publicity campaign to ensure prescribers are aware that – unlike small-molecule generics – biosimilars are not straight swaps for the originator products. Read More

Mount Tam Biotech to explore Buck Institute compound in SLE

Nearly two years after the Buck Institute for Research on Aging partnered with British firm Biotica Technology Ltd. to explore diseases of aging through the creation of Delos Pharmaceuticals Inc., a similar deal is afoot in the area of autoimmune disorders. Read More

Antibiotics side effects include later obesity, via gut microbiome

One of the biggest side effects of antibiotics may come not at the time of treatment, but years later. Scientists have shown that treatment with antibiotics early in life permanently altered the metabolism of mice, predisposing them to obesity. Read More

Genor, Biocnd moving Humira biosimilar into clinical testing

HONG KONG – A Chinese biopharma has received approval from South Korean regulators to conduct local clinical trials on its biosimilar drug. Genor Biopharma Co. Ltd., a subsidiary of Walvax Biotechnology Co. Ltd. since last October, received clinical trial approval from the Korean Ministry of Food and Drug Safety (MFDS) for GB232, a biosimilar version of Abbvie Inc.'s Humira. Read More

Venezuela's pharma sector in crisis, says local pharma group

BOGOTA, Colombia – As the political and economic situation worsens in Venezuela, pharmaceutical and biotech companies in the Latin American country are among the most affected by a lack of access to foreign currency. Read More

Financings

Resverlogix Corp., of Calgary, Alberta, closed the previously disclosed amendments which provided for the loan granted to the company by Citibank N.A. to be increased by $30 million to $68.8 million. Read More

Other news to note

Expression Therapeutics LLC, of Tucker, Ga., entered a deal with biomedical contract research and manufacturing organization ABL Inc., which will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy. Financial terms were not disclosed. Read More

Stock movers

Read More

In the clinic

Egalet Corp., of Wayne, Pa., said it completed an end-of-phase II meeting with the FDA regarding Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Read More

Appointments and advancements

Revance Therapeutics Inc., of Newark, Calif., named Arthur P. Bertolino executive vice president and chief medical officer. Read More

Pharma: Other news to note

Pfizer Inc., of New York, completed the submission of a new drug application to the FDA for palbociclib, requesting approval of the compound in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer who have not received previous systemic treatment for their advanced disease. Read More

Pharma: In the clinic

Pledpharma AB, of Stockholm, said the futility analysis in the study known as Pliant has been completed, and the data safety monitoring board found that the analysis turned up no negative impact on the anticancer effect of chemotherapy when the company's drug, Pledox (calmangafodipir), was used. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 20, 2025.
  • Brain, syringe hovering over hands

    NICE rejects Lilly‘s Kisunla and Eisai‘s Leqembi

    BioWorld
    To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe